Manufacture

Study investigates why vial choices matters for frozen biopharmaceutical storage.

So much has already been achieved with RNA – and it’s only going to get better.

AI is set to be a key disruptor in the pharma industry. Here are two perspectives on how it could change drug development.

Here’s why the Cell and Gene Therapy Catapult is excited about the potential of digital twin technology.

With new cases of avian influenza appearing, what does this mean for global health and what are drug developers doing about it?

Doing more to ease the challenges of antibody drug conjugate manufacturing.

Welcome back to our interview series with Jon Thomas, President and CEO of the California Institute for Regenerative Medicine: CIRM.

Who will be the grand winner of our 2024 Innovation Awards?

Accelerating the progress of cell and gene therapies with decentralized trials and other innovative approaches.

The trends and challenges in oral solid dosage formulations contribute to greater stability for drugs used by patients worldwide.